Advertisement


Joannie M. Ivory, MD, MSPH, and Lisa A. Carey, MD, on PAM50 Subtype and 21-Gene Recurrence Scores in Younger and Black Women With Breast Cancer

2022 San Antonio Breast Cancer Symposium

Advertisement

Lisa A. Carey, MD, and Joannie M. Ivory, MD, MSPH, both of the University of North Carolina at Chapel Hill, discuss the higher frequency and treatment implications of nonluminal A or high-risk tumors in Black and younger women. In this study, PAM50 and 21-gene assays revealed different demographic patterns by race and age (Abstract PD1-08).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Lisa Carey, MD: One of the pleasures of working at the University of North Carolina has been the Carolina Breast Cancer Study, which has given us enormous information over a number of decades about breast cancer risk and behavior, particularly in young women and people of color, specifically Black women. More recently, the biology has been even further defined with some efforts to look at genomic assays by race and by age. Joannie, you've been part of an analysis that came out in San Antonio this year. Do you want to talk a little bit about that? Joannie Ivory, MD: Absolutely. We did a update of the Carolina Breast Cancer Study analysis. What that showed was that women who were Black had a higher frequency of non-luminal A tumors, as well as younger women. They had a higher frequency of non-luminal A tumors, as well. The importance of this is that this can have treatment implications, because as we know, the tumors that are non-luminal A, they tend to be more endocrine-resistant. Taken into consideration, this was all done in early-stage breast cancer. What I think we need to do is expand and actually look at these relationships in metastatic breast cancer. Lisa Carey, MD: Joannie, let me push you a little bit on that. Early breast cancer, the non-luminal As include luminal B, HER2-enriched basal-like. Joannie Ivory, MD: Mm-hmm. Lisa Carey, MD: Can you talk a little bit more about what does it mean to be luminal B or HER2-enriched or basal-like? Joannie Ivory, MD: Yeah. The most common breast cancer is ER-positive, HER2-negative breast cancer. Usually, that correlates with luminal A tumors. When you get more so to the basal-like tumors, they pretty much behave like triple-negative breast cancer, and so that's why they're a little bit more resistant to endocrine therapy. I think this is an emergent field where we are actually starting to use this to assess whether or not this can guide treatment in the future. Lisa Carey, MD: Yeah, I mean some studies are testing whether or not, in fact, in basal-like tumors, you should be using chemotherapy, regardless of what the receptor phenotype is. I should be very clear that the analysis that was done of the Carolina Breast Cancer Study was only in the hormone receptor-positive, HER2-negative group, where this starts to become particularly important to know. Talk a little bit about the Lineberger study called HARMONY, and what that's doing and your part of that. Joannie Ivory, MD: The HARMONY trial at Lineberger, it's pretty much an interventional study at this single institution. What we're doing is we're determining the intrinsic subtypes of the tumor in the metastatic setting. What we're going to do is we're going to get the intrinsic subtype of the primary tumor and also of the metastatic tumor and see if there's a concordance between the two. Then what we're also going to do is that once the patient goes and see their provider, they're going to treat the patient as they normally would, but then we're going to give the treating providers the intrinsic subtype information, and then do a survey and see how this changes their decision in a second-line setting. Lisa Carey, MD: Right. I think the implication here is if you see more non-luminal As the Carolina Breast Cancer Study showed in the early setting, if you're seeing this also in the metastatics, saying we may see even more discordance in the metastatic setting in Black women, and parenthetically, also young women. Joannie Ivory, MD: Absolutely. This is also something that I will be studying myself for my ASCO YIA research proposal where we're actually going to look at the race and age relationship of the intrinsic subtypes in the HARMONY trial to see if the same relationship that was seen in early breast cancer is upheld in a metastatic setting. Lisa Carey, MD: Fantastic, fantastic. I think it's going to be super important, and I think in so many of the trials, things that were shown at San Antonio, there's so few Black women represented in the trials, and so we really have to use our population-based studies to illuminate this a little bit more. Joannie, thank you so much for everything you're doing. I look forward to these really interesting analyses. Joannie Ivory, MD: Thank you.

Related Videos

Breast Cancer

François-Clément Bidard, MD, PhD: Circulating Tumor Cells May Help Improve Outcomes in Metastatic Disease

François-Clément Bidard, MD, PhD, of the Institut Curie, discusses overall survival results from the STIC CTC trial. To guide the choice between chemotherapy and endocrine therapy for patients with metastatic, estrogen receptor–positive/HER2-negative breast cancer, researchers compared circulating tumor cell (CTC) count to physician’s choice of treatment. The data suggest that the CTC count resulted in better long-term outcomes (Abstract GS3-09).

Breast Cancer

Erica L. Mayer, MD, PhD, on Metastatic Breast Cancer: New Findings on Palbociclib After Prior CDK4/6 Inhibitor and Endocrine Therapy

Erica L. Mayer, MD, PhD, of Dana-Farber Cancer Institute, discusses findings from the PACE study of patients with endocrine- and CDK4/6 inhibitor–pretreated estrogen receptor–positive/HER2-negative metastatic breast cancer who were randomly assigned to fulvestrant alone; fulvestrant and palbociclib; or fulvestrant, palbociclib, and avelumab. Combining palbociclib with fulvestrant beyond disease progression on a prior CDK4/6 inhibitor regimen did not improve progression-free survival compared with fulvestrant alone. A longer progression-free survival when a PD-L1 inhibitor was added to fulvestrant and palbociclib deserves further study. A baseline circulating tumor DNA analysis suggests that the potential benefit of palbociclib after progression on a prior CDK4/6 inhibitor may be influenced by ESR1 or PIK3CA status (Abstract GS3-06).

Breast Cancer

Ann H. Partridge, MD, MPH, on Interrupting Breast Cancer Treatment to Attempt Pregnancy

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the POSITIVE trial, which showed that a temporary interruption of endocrine therapy in women with hormone-responsive breast cancer in order to attempt pregnancy, does not affect short-term disease outcomes. The study found that 74% of women had at least one pregnancy, most (70%) within 2 years. Birth defects were low (2%) and were not clearly associated with treatment exposure. Dr. Partridge explains that these data stress the need to incorporate patient-centered reproductive health care in the treatment and follow-up of young women with breast cancer (Abstract GS4-09).

Breast Cancer

Joseph A. Sparano, MD, on Long-Term Breast Cancer Recurrence and Survival Data from TAILORx

Joseph A. Sparano, MD, of the Tisch Cancer Center at Mount Sinai Health System, discusses long-term clinical outcomes data that continue to show many women with early breast cancer can safely forgo chemotherapy, when guided by the 21-gene recurrence score result. The longer follow-up also showed that recurrences of breast cancer continue to occur years after the original diagnosis, although these recurrences were not prevented by chemotherapy use. Racial disparities were not explained by inequities in social determinants of health or treatment adherence, with Black women at higher risk of early recurrence within the first 5 years of diagnosis, but not later recurrence after 5 years (Abstract GS1-05).

Breast Cancer

Ruth O’Regan, MD, on Evaluation of the Breast Cancer Index in Early-Stage Breast Cancer

Ruth O’Regan, MD, of the University of Rochester Medical Center, discusses the Breast Cancer Index (BCI), a genomic assay that can assess the risk of late distant recurrence (5–10 years after diagnosis) of hormone receptor–positive, early-stage breast cancer. Among premenopausal women with this disease who were enrolled in the SOFT trial, those with a high BCI score had an increased risk of distant recurrence. Those with a low BCI score benefited more from the addition of ovarian suppression therapy to endocrine therapy after 12 years of follow-up (Abstract GS1-06).

Advertisement

Advertisement



Advertisement